Your browser doesn't support javascript.
loading
GlycA, a novel marker for low grade inflammation, reflects gut microbiome diversity and is more accurate than high sensitive CRP in reflecting metabolomic profile.
Mokkala, Kati; Houttu, Noora; Koivuniemi, Ella; Sørensen, Nikolaj; Nielsen, Henrik Bjørn; Laitinen, Kirsi.
Afiliación
  • Mokkala K; Institute of Biomedicine, Research Centre for Integrative Physiology and Pharmacology, University of Turku, 20014, Turku, Finland. kamamo@utu.fi.
  • Houttu N; Institute of Biomedicine, Research Centre for Integrative Physiology and Pharmacology, University of Turku, 20014, Turku, Finland.
  • Koivuniemi E; Institute of Biomedicine, Research Centre for Integrative Physiology and Pharmacology, University of Turku, 20014, Turku, Finland.
  • Sørensen N; Clinical Microbiomics, Copenhagen, Denmark.
  • Nielsen HB; Clinical Microbiomics, Copenhagen, Denmark.
  • Laitinen K; Institute of Biomedicine, Research Centre for Integrative Physiology and Pharmacology, University of Turku, 20014, Turku, Finland.
Metabolomics ; 16(7): 76, 2020 06 20.
Article en En | MEDLINE | ID: mdl-32564244
INTRODUCTION: Gut microbiota is, along with adipose tissue, recognized as a source for many metabolic and inflammatory disturbances that may contribute to the individual's state of health. OBJECTIVES: We investigated in cross-sectional setting the feasibility of utilizing GlycA, a novel low grade inflammatory marker, and traditional low grade inflammatory marker, high sensitivity CRP (hsCRP), in reflecting serum metabolomics status and gut microbiome diversity. METHODS: Fasting serum samples of overweight/obese pregnant women (n = 335, gestational weeks: mean 13.8) were analysed for hsCRP by immunoassay, GlycA and metabolomics status by NMR metabolomics and faecal samples for gut microbiome diversity by metagenomics. The benefits of GlycA as a metabolic marker were investigated against hsCRP. RESULTS: The GlycA concentration correlated with more of the metabolomics markers (144 out of 157), than hsCRP (55 out of 157) (FDR < 0.05). The results remained essentially the same when potential confounding factors known to associate with GlycA and hsCRP levels were taken into account (P < 0.05). This was attributable to the detected correlations between GlycA and the constituents and concentrations of several sized VLDL-particles and branched chain amino acids, which were statistically non-significant with regard to hsCRP. GlycA, but not hsCRP, correlated inversely with gut microbiome diversity. CONCLUSION: GlycA is a superior marker than hsCRP in assessing the metabolomic profile and gut microbiome diversity. It is proposed that GlycA may act as a novel marker that reflects both the gut microbiome and adipose tissue originated metabolic aberrations; this proposal will need to be verified with regard to clinical outcomes. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT01922791, August 14, 2013.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Microbioma Gastrointestinal / Inflamación Tipo de estudio: Diagnostic_studies / Observational_studies / Prevalence_studies / Risk_factors_studies Límite: Adult / Female / Humans / Pregnancy Idioma: En Revista: Metabolomics Año: 2020 Tipo del documento: Article País de afiliación: Finlandia Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Microbioma Gastrointestinal / Inflamación Tipo de estudio: Diagnostic_studies / Observational_studies / Prevalence_studies / Risk_factors_studies Límite: Adult / Female / Humans / Pregnancy Idioma: En Revista: Metabolomics Año: 2020 Tipo del documento: Article País de afiliación: Finlandia Pais de publicación: Estados Unidos